Project Details
Description
Clinical product development and IND enabling studies for a PIK3CA (H1047L) TCR transgenic autologous T cell immunotherapy for the treatment of advanced cancers in HLA-A*03:01+ subjects.
| Status | Finished |
|---|---|
| Effective start/end date | 5/1/22 → 4/30/24 |
Funding
- INTIMA BIOSCIENCES, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.